Physician profile
James E Burleson
NPI 1629174321
$5,593.18
in general payments reported to CMS, 2019-2025
42 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $255 · 2021: $404 · 2022: $955 · 2023: $938 · 2024: $1,061 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,273.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,029.25 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $645.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $528.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $460.79 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Corium, LLC | $327.68 | 2023-2025 | Azstarys |
| Novo Nordisk INC | $287.96 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $252.88 | 2019-2025 | Airsupra, Flumist Quadrivalent, Farxiga |
| Astellas Pharma US INC | $208.80 | 2022-2025 | Veozah |
| Axsome Therapeutics, INC. | $187.78 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $156.91 | 2022-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.70 | 2019-2023 | Jardiance |
| Amgen INC. | $146.60 | 2019-2025 | Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.81 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $114.52 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.33 | 2022-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Burleson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.